Scottish Medicines Consortium
Providing advice about the status of all newly licensed medicines
www.scottishmedicines.org.uk
Delta House 50 West Nile Street Glasgow G1 2NP Tel 0141 225 6999 Chairman: Professor Jonathan G Fox
NHS SCOTLAND

Statement of Advice:

elotuzumab (Empliciti®) 300mg and 400mg powder for concentrate for solution for infusion (No: 1183/16)

Bristol Myers Squibb Pharmaceutical Limited

8 July 2016

ADVICE: in the absence of a submission from the holder of the marketing authorisation

elotuzumab (Empliciti®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of multiple myeloma in combination with lenalidomide and dexamethasone in adult patients who have received at least one prior therapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman,
Scottish Medicines Consortium

Published 08 August 2016